Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma. - Université de Rennes Accéder directement au contenu
Article Dans Une Revue European Urology Année : 2008

Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.

Naeem Bhojani
  • Fonction : Auteur
Claudio Jeldres
  • Fonction : Auteur
Paul Perrotte
  • Fonction : Auteur
Nazareno Suardi
  • Fonction : Auteur
Georg Hutterer
  • Fonction : Auteur
François Patenaude
  • Fonction : Auteur
Stéphane Oudard
  • Fonction : Auteur
Pierre I Karakiewicz
  • Fonction : Auteur

Résumé

OBJECTIVE: To provide a systematic review of the side effects associated with sorafenib, sunitinib, and temsirolimus and to provide an outline of possible preventive or therapeutic measures. METHODS: We performed a PubMed-based systematic review of side effects associated with the three agents and relied on product monographs and prescribing information to provide an outline of treatments aimed at reducing these toxicities. RESULTS: Side effects range from <1% to 72%. Grade 3/4 side effects are less common and range from <1% to 13% for sorafenib, <1% to 16% for sunitinib, and 1% to 20% for temsirolimus. Overall, sunitinib causes the most grade 3/4 side effects and sorafenib causes the fewest grade 3/4 side effects, although head-to-head trials are required to compare safety profiles of all three kinase inhibitors. Virtually all side effects can be managed effectively. CONCLUSION: Prevention, recognition, and prompt management of side effects are of key importance and avoid unnecessary dose reductions, which may undermine treatment efficacy.

Dates et versions

hal-00277571 , version 1 (06-05-2008)

Identifiants

Citer

Naeem Bhojani, Claudio Jeldres, Jean-Jacques Patard, Paul Perrotte, Nazareno Suardi, et al.. Toxicities associated with the administration of sorafenib, sunitinib, and temsirolimus and their management in patients with metastatic renal cell carcinoma.. European Urology, 2008, 53 (5), pp.917-30. ⟨10.1016/j.eururo.2007.11.037⟩. ⟨hal-00277571⟩
52 Consultations
0 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More